Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Director Sells $131,900.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Director Saira Ramasastry sold 10,000 shares of the stock in a transaction on Friday, June 21st. The shares were sold at an average price of $13.19, for a total value of $131,900.00. Following the completion of the transaction, the director now directly owns 40,485 shares of the company’s stock, valued at $533,997.15. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Day One Biopharmaceuticals Stock Down 1.1 %

Shares of DAWN opened at $13.53 on Tuesday. Day One Biopharmaceuticals, Inc. has a 52-week low of $9.67 and a 52-week high of $18.07. The company has a market capitalization of $1.18 billion, a PE ratio of -5.39 and a beta of -1.53. The stock has a fifty day simple moving average of $14.67 and a two-hundred day simple moving average of $14.75.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). As a group, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.69 earnings per share for the current fiscal year.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth about $29,000. Quintet Private Bank Europe S.A. increased its position in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Day One Biopharmaceuticals by 352.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock worth $147,000 after purchasing an additional 7,841 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in Day One Biopharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after acquiring an additional 2,554 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $156,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on DAWN. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, June 20th. Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. JPMorgan Chase & Co. increased their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. Finally, The Goldman Sachs Group cut their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and an average price target of $37.67.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.